The trial will study the efficacy of IDCT — an allogenic, injectable disc cell therapy — in treating mild to moderate degenerative disc disease.
An independent data safety monitoring company gave the all-clear after it completed a final mid-trial safety review following the treatment of the first six subjects in the high dose study group.
DiscGenics plans to treat a total of 60 subjects in the clinical study.
More articles on biologics:
Dr. Erich Anderer discusses the impact of a single payer system in spine
Differences in Canadian, U.S. spine care: Q&A with Dr. Stephanie de Vere
Dr. Thomas Loftus: How a single-payer system would harm spine practice in the US
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
